Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Intestinal mucositis: mechanisms and management|
|Citation:||Current Opinion in Oncology, 2007; 19(4):323-327|
|Publisher:||Lippincott Williams & Wilkins|
|Abstract:||Purpose of review: To describe the advances in the rapidly evolving field of intestinal (or alimentary) mucositis during the past year. Recent findings: Major advances have been made in both the clinical and preclinical setting, with the publication of a suite of articles regarding the pathobiology and management of mucositis, as well as several articles on important basic research in the area. The mechanism of mucositis development is now understood to be much more complex than previously thought, with an interplay of host and drug factors leading to overt damage, and variation in manifestation of that damage depending on the specific region of the gut. The MASCC/ISOO management guidelines for mucositis have been updated: a recommendation for the use of palifermin in the hematology transplant setting has been added, and a couple of previous recommendations have been revoked. This marks an important milestone in mucositis, as it is the first time a drug has been available that substantially reduces the occurrence and severity of mucositis. Summary: There is still much to be done to abolish the severe toxicity of chemotherapy and radiotherapy; however, progress is accelerating, and new targeted drugs are becoming available.|
Combined Modality Therapy
Practice Guidelines as Topic
|Description:||Copyright © 2008, Lippincott Williams & Wilkins.|
|Appears in Collections:||Aurora harvest 6|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.